Allergen immunotherapy during the COVID‐19 pandemic—A survey of the German Society for Allergy and Clinical Immunology

Pfaar, Oliver; Hamelmann, Eckard; Klimek, Ludger; Taube, Christian; Vogelberg, Christian; Wagenmann, M.; Werfel, Thomas; Worm, Margitta

doi:10.1002/clt2.12134

Cited by 9 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 198 During COVID‐19, AIT was initiated and continued by most physicians in patients without indications of SARS‐CoV‐2 infection. 199 In contrast, lockdown during COVID‐19 resulted in decreased numbers of patients initiating AIT but without significant impact on sublingual immunotherapy. 200 …”

Section: Management Of Allergic Diseases During the Covid‐19 Pandemicmentioning

confidence: 99%

“…Dupilumab seems to be safe and crucial for a better outcome of COVID‐19 and should be continued in AD patients during the COVID‐19 pandemic 198 . During COVID‐19, AIT was initiated and continued by most physicians in patients without indications of SARS‐CoV‐2 infection 199 . In contrast, lockdown during COVID‐19 resulted in decreased numbers of patients initiating AIT but without significant impact on sublingual immunotherapy 200 …”

Section: Management Of Allergic Diseases During the Covid‐19 Pandemicmentioning

confidence: 99%

See 1 more Smart Citation

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy of the COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID-19.

show abstract

Section: Management Of Allergic Diseases During the Covid‐19 Pandemicmentioning

confidence: 99%

Section: Management Of Allergic Diseases During the Covid‐19 Pandemicmentioning

confidence: 99%

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

show abstract

“…Current studies demonstrated adherence by clinicians to national and international position papers and guidelines of allergen immunotherapy during the COVID-19 pandemic worldwide. Besides, several surveys/research have shown good tolerability of allergen immunotherapy for both subcutaneous and sublingual-oral forms [18].…”

Section: Asthmamentioning

confidence: 99%

Perspective Chapter: Management of Allergic Diseases during Pandemic

Özdemir¹,

Yılmaz²

2023

Allergic Disease - New Developments in Diagnosis and Therapy

View full text Add to dashboard Cite

Over the recent time period, pediatric allergy clinics across the world have markedly changed their practice because of the COVID-19 pandemic. Nowadays, clinics are not inclined to accept a patient demanding a new procedure / therapeutic modality during pandemic. All allergic diseases require continuous management and treatment, and their socioeconomic burden has been increasing worldwide. In this chapter, the aim is to focus on allergic diseases management during pandemic. During this time, patient follow-up, patient management, and diagnostic tests are real challenges. Limited face-to-face consultations and as much as use of telemedicine are currently seen as the major issues in the allergy practice. Face-to-face examination and treatment should be preferred only in vital situations. During COVID-19 pandemic, patient education, which is the most important step in the treatment of allergic diseases, has started to be done online. The prevailing opinion in the allergy community is that the treatment should not be interrupted, or dose reduction should not be made. According to the guidelines, it is appropriately recommended to carefully calculate the profit and loss of the treatment on a case-by-case basis.

show abstract

“…In addition, straightforward and consensus-based recommendations for both SCIT- and SLIT-treated patients have been proposed internationally [ 69 ] and have also been adapted to the situation in German-speaking countries [ 70 ]. However, a high grade of heterogeneity of adherence to the academic guidance given has been found in international [ 71 ] and national [ 72 ] surveys on COVID-19 and AIT suggesting some undertreatment of patients.…”

Section: Ait During the Covid-19 Pandemicmentioning

confidence: 99%

111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases

Gutermuth¹,

Grosber²,

Pfaar

et al. 2022

ALS

View full text Add to dashboard Cite

The great milestones in medicine almost always have their precursors, which help the great event to break through. So it was with allergen-specific immunotherapy (AIT) and the great work of Noon and Freeman and their world-renowned publication in 1911. In this article, we want to outline AIT’s long journey, from early attempts to achieve tolerance to allergens in the environment. Many very different methods were used; from homeopathy to the use of recombinant allergens. Initially, the allergen extracts were given only subcutaneously, but then also through other routes, such as nasal, rectal, intradermal, epicutaneous, in lymph nodes, or oral. It was the great merit of Bill Franklin, whom many of us still experienced as active participants in congresses, to point out that the effect of AIT must be documented not only by clinical observation but in a controlled form including placebo injections. AIT was thus transferred to evidence-based medicine, which we successfully apply today. We would like to express our gratitude to Bill Franklin himself and all others involved in the development of AIT with this summary of 111 years of immunotherapy.

show abstract

Allergen immunotherapy during the COVID‐19 pandemic—A survey of the German Society for Allergy and Clinical Immunology

Cited by 9 publications

References 27 publications

Recent developments in the immunopathology of COVID‐19

Recent developments in the immunopathology of COVID‐19

Perspective Chapter: Management of Allergic Diseases during Pandemic

111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases

Contact Info

Product

Resources

About